Diatrizoic acid
Cystografin, Diatrizoate Diatrizoate, Gastrografin, Hypaque, Md, Md-gastroview, Sinografin, Urovist (diatrizoic acid) is a small molecule pharmaceutical. Diatrizoic acid was first approved as Cystografin on 1982-01-01.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Combinations
Diatrizoate meglumine diatrizoate, Gastrografin, Md-gastroview (discontinued: Angiovist, Diatrizoate, Gastrovist, Hypaque, Md, Md-76r, Renocal)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Diatrizoate sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| HYPAQUE | GE Healthcare | N-011386 DISCN | 1982-01-01 | 2 products |
| HYPAQUE | GE Healthcare | N-009561 DISCN | 1982-01-01 | 1 products |
| HYPAQUE SODIUM 20% | GE Healthcare | N-009561 DISCN | 1982-01-01 | 1 products |
| HYPAQUE | GE Healthcare | N-009561 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Diatrizoate meglumine
+
Diatrizoate sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| GASTROGRAFIN | Bracco Diagnostics | N-011245 RX | 1982-01-01 | 1 products, RLD, RS |
Show 3 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cystografin | New Drug Application | 2018-04-15 |
| cystografin dilute | New Drug Application | 2018-10-02 |
| diatrizoate meglumine and diatrizoate sodium | ANDA | 2024-04-23 |
| gastrografin | New Drug Application | 2021-10-04 |
| hypaque | 2006-04-13 | |
| hypaque - cysto | 2007-08-03 | |
| hypaque sodium | 2007-08-03 | |
| md gastroview | ANDA | 2021-01-01 |
| md-gastroview | ANDA | 2014-09-29 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
43 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Intestinal obstruction | D007415 | — | K56.60 | — | 1 | 2 | 3 | 5 | 10 |
| Gallstones | D042882 | EFO_0004210 | — | — | — | — | 1 | 1 | 2 |
| Cholelithiasis | D002769 | EFO_0004799 | K80 | — | — | — | 1 | 1 | 2 |
| Cholecystolithiasis | D041761 | EFO_1000864 | — | — | — | — | 1 | 1 | 2 |
| Ileus | D045823 | — | — | — | 1 | 1 | 1 | — | 2 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | — | — | — | 1 | — | 1 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | — | — | 1 | — | 1 |
| Healthy volunteers/patients | — | — | — | — | — | — | 1 | — | 1 |
| Congenital abnormalities | D000013 | EFO_0003915 | Q89.9 | — | — | — | 1 | — | 1 |
| Gastroschisis | D020139 | EFO_1000949 | Q79.3 | — | — | — | 1 | — | 1 |
Show 4 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 2 | 2 | — | — | 2 |
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | 1 | 2 | 1 | — | — | 2 |
| Dilated cardiomyopathy | D002311 | HP_0001644 | I42.0 | 1 | 2 | 1 | — | — | 2 |
| Colonic neoplasms | D003110 | — | C18 | — | — | 1 | — | 1 | 2 |
| Insulin resistance | D007333 | HP_0000855 | — | — | 1 | 1 | — | — | 1 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | 1 | 1 | — | — | 1 |
| Infertility | D007246 | HP_0000789 | — | — | — | 1 | — | — | 1 |
| Flushing | D005483 | — | R23.2 | — | — | 1 | — | — | 1 |
| Pathologic constriction | D003251 | — | — | — | — | 1 | — | — | 1 |
| Urethral stricture | D014525 | HP_0012227 | — | — | — | 1 | — | — | 1 |
Show 3 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Constipation | D003248 | HP_0002019 | K59.0 | — | 1 | — | — | — | 1 |
| Fecal impaction | D005244 | — | K56.41 | — | 1 | — | — | — | 1 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | 1 | 1 | — | — | — | 1 |
| Fibrosis | D005355 | — | — | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Behcet syndrome | D001528 | EFO_0003780 | M35.2 | 1 | — | — | — | — | 1 |
| Retinitis | D012173 | — | H30.9 | 1 | — | — | — | — | 1 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | 1 | — | — | — | — | 1 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | 1 | — | — | — | — | 1 |
| Adenocarcinoma | D000230 | — | — | 1 | — | — | — | — | 1 |
| Adenocarcinoma of lung | D000077192 | — | — | 1 | — | — | — | — | 1 |
| Cellular immunity | D007111 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Esophageal achalasia | D004931 | HP_0002571 | K22.0 | — | — | — | — | 2 | 2 |
| Colorectal neoplasms | D015179 | — | — | — | — | — | — | 2 | 2 |
| Underactive urinary bladder | D000077295 | — | — | — | — | — | — | 2 | 2 |
| Hypokinesia | D018476 | — | — | — | — | — | — | 2 | 2 |
| Urinary bladder neck obstruction | D001748 | EFO_1000840 | N32.0 | — | — | — | — | 2 | 2 |
| Cystocele | D052858 | — | — | — | — | — | — | 2 | 2 |
| Esophageal motility disorders | D015154 | — | K22.4 | — | — | — | — | 1 | 1 |
| Muscle spasticity | D009128 | HP_0001257 | — | — | — | — | — | 1 | 1 |
| Diffuse esophageal spasm | D015155 | EFO_1001785 | K22.4 | — | — | — | — | 1 | 1 |
| Esophageal diseases | D004935 | EFO_0009544 | K22.9 | — | — | — | — | 1 | 1 |
Show 15 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Diatrizoic acid |
| INN | sodium amidotrizoate |
| Description | Amidotrizoic acid is a member of the class of benzoic acids that is benzoic acid having iodo substituents at the 2-, 4- and 6-positions and acetamido substituents at the 3- and 5-positions. It is used, mainly as its N-methylglucamine and sodium salts, as an X-ray contrast medium in gastrointestinal studies, angiography, and urography. It has a role as a radioopaque medium, an environmental contaminant and a xenobiotic. It is an organoiodine compound, a member of benzoic acids and a member of acetamides. It is a conjugate acid of an amidotrizoic acid anion. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(=O)O)c1I |
Identifiers
| PDB | — |
| CAS-ID | 117-96-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201220 |
| ChEBI ID | 53691 |
| PubChem CID | 2140 |
| DrugBank | DB00271 |
| UNII ID | V5403H8VG7 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 33,199 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
366 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use